TGFBR1 and neoplasm: Noticeably, LY treatment at a dose of 1.5 mg/kg dramatically reduced ~2.0-fold of M2-type tumor-associated macrophages (TAM) to increase M1-type macrophages by ~5.0-fold, indicating that TGFR1 inhibition can also relieve TAMs-induced immune resistance (Supplementary Fig. 13).